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SUMMARY
Chlamydia trachomatis is the most common bacterial sexually
transmitted pathogen worldwide. Infection can result in serious
reproductive pathologies, including pelvic inflammatory disease,
ectopic pregnancy, and infertility, in women. However, the pro-
cesses that result in these reproductive pathologies have not been
well defined. Here we review the evidence for the human disease
burden of these chlamydial reproductive pathologies. We then
review human-based evidence that links Chlamydia with repro-
ductive pathologies in women. We present data supporting the
idea that host, immunological, epidemiological, and pathogen
factors may all contribute to the development of infertility. Spe-
cifically, we review the existing evidence that host and pathogen
genotypes, host hormone status, age of sexual debut, sexual be-
havior, coinfections, and repeat infections are all likely to be con-
tributory factors in development of infertility. Pathogen factors
such as infectious burden, treatment failure, and tissue tropisms
or ascension capacity are also potential contributory factors. We
present four possible processes of pathology development and
how these processes are supported by the published data. We
highlight the limitations of the evidence and propose future stud-
ies that could improve our understanding of how chlamydial in-
fertility in women occurs and possible future interventions to re-
duce this disease burden.
INTRODUCTION
Chlamydia trachomatis infection is one of the most commonbacterial sexually transmitted infections (STIs) worldwide,
with the WHO’s most recent estimates indicating approximately
100 million new infections annually (1); in the United States
alone, approximately 1.4 million Chlamydia infections occurred
in 2013 (2). C. trachomatis is a Gram-negative, obligate intracel-
lular bacterial pathogen with a unique biphasic developmental
cycle (3). The organism has been characterized by using biology
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and genomics as a highly evolved or ancient pathogen with evi-
dence of a reduced genome that is tailored for the obligate intra-
cellular human niche (4). The infection can result in serious re-
productive consequences, including pelvic inflammatory disease
(PID), ectopic pregnancy, and infertility, in women. GenitalChla-
mydia infection is asymptomatic in over 70% of the cases, and as a
result, fewpopulation-based prevalence or incidence estimates are
available (5). Available population-based data from the United
States, Australia, and the United Kingdom suggest that between 3
and 5% of people under 30 years of age will have a Chlamydia
infection at any point in time (6–10). Estimates of the incidence of
disease sequelae (specifically, PID, ectopic pregnancy, and infer-
tility in women) are lacking, largely because there are very few
natural-history studies ofChlamydia infections in humans. A sys-
tematic review attempting to establish the attributable risk of
infertility among women following genital Chlamydia infection
concluded that there is currently not sufficient evidence to accu-
rately determine the population attributable risk (11). Surveil-
lance of infertility on a population level is very limited, and thus it
is difficult to ascertain whether an increased incidence of Chla-
mydia infection (or indeed the increased detection and treatment
of infections) is associated with concurrent trends in infertility.
However, there is robust evidence that women who have
experienced PID are more likely to develop infertility and ro-
bust evidence thatChlamydia infection causes PID. Specifically, a
longitudinal cohort studywas conducted byWeströmet al. (12) to
evaluate PID and fertility outcomes. The study followed 1,844
women with abnormal laparoscopic findings upon suspicion of
acute PID (case subjects; not limited to Chlamydia infection) and
657womenwhohadnormal findings (controls). Follow-up found
that upon attempting to become pregnant, 16.5% of the case sub-
jects and 2.7% of the controls failed to conceive (12). Further
investigations demonstrated that 141 (10.8%) of the PID case sub-
jects andnone of the controls had developed tubal factor infertility
(TFI) (12). In addition, the ectopic pregnancy rate was also higher
in the PID case subjects, with 9.1%of the case subjects and 1.4%of
the controls experiencing ectopic pregnancy (12). However, this
study did not detail the infectious agent underlying the initial PID.
A randomized controlled trial to evaluate if chlamydial screen-
ing can prevent PID (prevention of pelvic infection trial) found
that the risk of PID among women whose Chlamydia infections
were left untreated was 9.5%, considerably higher than the 1.6%
risk of PID among women whose infections were treated (13).
Mathematical modeling suggested that PID can occur at any time
point during the natural history of an infection; therefore, annual
chlamydial screening programs may reduce the incidence of PID
(14). A separate model concluded that annual screening could
prevent 61% (95% credible interval, 55 to 67%) of Chlamydia-
associated PID (15).
The risk of infertility due toChlamydia infection ismuch lower
than that of PID; for example, in Sweden, using a retrospective
hospital record review process, it was found that women who had
a positive Chlamydia test had an adjusted hazards ratio of 1.31
(95% confidence interval, 1.09 to 1.57; P  0.0001) of having
infertility compared to women who tested negative for Chla-
mydia, although there was no significant difference in ectopic
pregnancy outcomes (16). The performance of the serological
tests that are commonly used in conjunction with gynecological
investigation to attribute infertility to Chlamydia is one of the
limitations of the assessment of the burden of chlamydial infertil-
ity. However, a meta-analysis conducted in 2011 compared mi-
cro-immunofluorescence (MIF) tests and several enzyme-linked
immunosorbent assays (ELISAs) and found thatMIF tests had the
highest accuracy (area under the curve) for a positive reaction in
women with tubal pathology (P  0.001; P  0.01 for bilateral
occlusion) (17). Regardless of test performance, numerous studies
have identified a correlation of Chlamydia serology positivity
(Chlamydia antibody testing) with diagnosed TFI (18–24). Anal-
ysis of these published data by using a model estimated that the
proportion of tubal infertility caused by Chlamydia is 45% (cred-
ible interval, 28 to 62%) (25).
In spite of the considerable worldwide burden of chlamydial
disease, the host and pathogen determinants that result in infer-
tility are still not known. It is possible that identification of the risk
factors for the development of serious sequelae could be used to
implement additional targeted screening and treatment of at-risk
women to reduce the burden of this disease. Furthermore, recent
exciting advances have been made in the development of a chla-
mydial vaccine (26); however, it will be critical to establish that
any vaccine will not have unwanted consequences for reproduc-
tive pathology in some women. Therefore, in order to inform
future developments in the field, we have chosen to focus this
review specifically on infertility in women. Infertility is defined as
the inability to have a healthy live baby after 12 months of unpro-
tected timed intercourse. The majority of the studies reviewed for
this report state their definition of infertility as inability to achieve
successful pregnancy after12 months of unprotected sex. Some
studies refer to subfertility, which is defined as reduced fertility
with a prolonged time of unwanted nonconception, and we con-
sider this compatible with infertility for the purpose of this review.
PID and ectopic pregnancy are also reviewed here, with ectopic
pregnancy defined as tubal development of the embryo. In order
to identify what is known and what is not known about the host
and pathogen factors that result in the development of infertility
in women, we used PUBMED searches to identify and review the
relevant literature to generate this review (focusing on direct hu-
man evidence). Our aim is to highlight the most solid or consis-
tently identified factors that are known already and to identify the
gaps in our knowledge of the risk factors that could predict or
determine infertility outcomes in women that should be ad-
dressed in future studies to ensure optimal vaccine design and
inform improved diagnostics.
CHLAMYDIAL FACTORS THAT MAY INFLUENCE THE
DEVELOPMENT OF PATHOLOGY
Chlamydial Serovars Can Associate with Repeat Infection
and Symptoms That May Also Relate to a Propensity To
Cause Pathology and Infertility
Chlamydial serovars are assigned on the basis of the immune
response to the major outer membrane protein and typically in
more recent work by sequencing this locus (27). Serovars E and
F are generally found to be predominant in most countries,
including Australia, Netherlands, and Sweden (28–32). Using
omp1 PCR-based restriction fragment length polymorphism
genotyping, Lan et al. (33) reported that in women 30 years
old, serovars D (4/21 asymptomatic women) and I (4/21
asymptomatic women) were associated with asymptomatic in-
fection, while serovar G was associated with symptomatic in-
fection (4/30 symptomatic cases). Similarly, Gao et al. (30) also
Menon et al.
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reported the predominance of serovar G in symptomatic infec-
tion, particularly lower abdominal pain (18/33 patients), com-
pared to asymptomatic patients (P 0.001) among female sex
workers and sexually transmitted disease (STD) patients in
China. Of the asymptomatic patients, 47.5% (28/59) had sero-
var E (30). Verweij et al. reported that different serovars in-
duced differential serological responses in 510 women with
PCR-confirmed C. trachomatis infection (34). Their study
showed that serovars D (n 45) and E (n 217) from serogroup
B elicited the highest IgG responses (median IgG titer of 200),
followed by serovar H (n  20) (34). Women with persisting
infections were found to have twice as may serovar E infections
(67%, 8/12) than women who naturally cleared their infections
(33%3/9) in a longitudinal study ofwomenwith asymptomaticC.
trachomatis infections; however, this was not a significant differ-
ence (35). However, several design flaws in the study done by
Morré et al. in 2002 have been pointed out and therefore it may
not be appropriate to draw conclusions from these data (e.g., see
references 36 and 37). It is important to note that some infected
women do not launch a detectable serological response against
elementary bodies (EBs) from several serovars or antigens (inde-
pendent of the infecting serovar), suggesting that not all infections
result in a detectable humoral immune response (38). While not
linked directly to infertility, the majority of the evidence from
these studies supports the idea that different serovars do have
different associations with symptoms, the immune response, re-
infection, or infection duration, all of which may contribute to
pathology development.
Chlamydial Genotypes Can Mediate Tissue Tropism and
May Be a Factor in Pathology Development
There are several published reports of C. trachomatis genotypic
differences associatingwith tissue tropismbut no data yet aligning
chlamydial genotypes with pathology development and infertility.
The best-known genotype that mediates tissue tropism is poly-
morphism in the trpAB operon, which disables the synthesis of
tryptophan from indole inC. trachomatis ocular strains but not in
genital strains (39, 40). It is mentioned here because of the signif-
icance of this finding to the field even though this review is focused
on infertility. There is also evidence of positively selected geno-
types that alignwith tissue tropism (ocular, genital, mononuclear/
invasive). For example, in a review of 59 C. trachomatis genome
sequences, it was reported that the Tarp gene and the pmp genes
have positively selected polymorphisms that cluster significantly
with tissue niches (41). Polymorphisms in three distinct open
reading frames have been found to associate with rectal but not
cervical serovar G isolates, and two further open reading frame
polymorphisms were found to associate with rectal and cervical
tropism of serovars E, F, and J (42). These studies do not identify
tissue pathology-associated polymorphisms; however, they do
support the theoretical potential for chlamydial genotypes to exist
that either increase the frequency of ascension or enhance upper
reproductive tract survival or polymorphisms that alter the im-
mune response. Determination of an association a chlamydial ge-
notype with pathology development would be possible only by a
longitudinal study of a large group of women throughout their
reproductive years with continual sampling and analysis of infect-
ing chlamydial strains.
IMMUNE RESPONSES ASSOCIATED WITH C. TRACHOMATIS
IN WOMEN
Insight into the immunological factors that may be involved in C.
trachomatis infertility in women has been obtained through vari-
ous human studies, including local secretions (cervical and vagi-
nal lavages), human tissues, and peripheral blood mononuclear
cells (PBMC), as well as through in vitro cell culturemodels. How-
ever, while numerous studies are mentioned here (but not all,
because of space limitations), many of these were on relatively
small numbers of patients or immune factors, and in fact, there is
very sparse evidence on the host immune response in womenwith
chlamydial infertility. The innate response to infection is clearly
critical for the infection outcome and, as outlined in the cellular
paradigm process (discussed below), could be the major determi-
nant of either a pathological result or resolution of the infection. A
framework commonly used to categorize the adaptive immune
response is the Th1-Th2 paradigm (reviewed in reference 43).
This paradigm suggests that the immune response can polarize
toward a cytotoxic response (Th1) or a humoral antibody-medi-
ated response (Th2). The profiles of these responses include the
Th1 subset of T helper (Th) lymphocytes and the production of
cytokines such as interleukin-2 (IL-2), IL-6, tumor necrosis factor
(TNF-), and gamma interferon (IFN-) (44, 45), and Th2 re-
sponses involve IL-4, IL-5, IL-6, IL-10, and IL-13 (44). In addition
to Th1-Th2, regulatory immune profiles typified by IL-17 or IL-23
have also recently been described (reviewed in reference 46). Here
we summarize the existing evidence on the human immune re-
sponse to C. trachomatis and how this evidence fits four different
possible processes of infertility development (presented at the end
of this review) by using these immune categories.
Immune Responses from Reproductive Sites and Tissues
Genital secretions have been used to reveal the immunological
responses that occur at the site of infection, although it is not
possible to link these with subsequent pathology. IFN- levels
were found to be five times as high in the endocervical secretions
of women with C. trachomatis infection detected by culture (n
47) as in those of uninfected women (n  52) (47). Analysis of
immune factors by a multiplex immunoassay in cervical-vaginal
lavage fluids of womenwith acuteC. trachomatis infection (n 5)
attending an STD clinic compared to those of controls with no
infections (n  13) revealed significantly higher levels of IL-1,
lactoferrin, TNF-, IL-8, vascular endothelial growth factor, gran-
ulocyte-colony stimulating factor (CSF), IL-10, IL-3, IL-7, IL-12,
and IL-6 (48). In another study in India, IFN- levels were signif-
icantly higher only in women with recurrent C. trachomatis infec-
tions than in controls but not higher than in those with primary
infections (49). IL-17 and IL-22 were five and three times as high
in the cervical secretions of C. trachomatis-positive women (n 
27) as in negative controls (n  17) (50). Titers of IgG and IgA
antibodies toC. trachomatisEBswere higher in the cervical washes
ofC. trachomatis-positive fertile women during primary infection
than during recurrent infection (49).However, the cervical titer of
IgG to specific chlamydial antigens (cHSP60 and cHSP10) was
higher in a recurrent infection than in a primary infection, which
is what would be expected (49). Flow cytometric analysis of lym-
phocytes present at the cervixes ofC. trachomatis-infected women
identified the increased presence of a unique cell type, 47
CLA memory T cells (51). Stimulation of cervical monocytes
Chlamydial Infertility in Women
October 2015 Volume 28 Number 4 cmr.asm.org 971Clinical Microbiology Reviews
 o
n
 February 25, 2016 by QUEENSLAND UNIV OF TECH
http://cm
r.asm
.org/
D
ow
nloaded from
 
with chlamydial EBs showed increased expression of Toll-like re-
ceptor 2 (TLR2) and TLR4, and both receptors were also found to
be expressed at higher levels in cervical cells from infected women
than in those from uninfected women (52). The levels of IL-1,
IL-4, IL-5, IL-6, and IL-10 were reported to be significantly higher
in enriched cervical T cells stimulated with chlamydial inclusion
(Inc) membrane proteins from women with C. trachomatis-re-
lated infertility (n  18) than in those from C. trachomatis-posi-
tive fertile women (n 14) (53). While ectopic pregnancy is not
only aChlamydia-related pathology, a study by Balasubramaniam
et al. that found that levels of the cytokines IL-8 and IL-6 were
significantly upregulated in the fallopian tubes immediately at
the location of implantation of ectopic pregnancy but not in
the fallopian tubes of women undergoing benign hysterectomy
(54). A very recent study found that differences in IFN- levels
correlated with differences in the chlamydial cellular morphol-
ogies at the cervix when comparing two patients (55). In sum-
mary, the consistent findings of these studies are that IFN-,
IL-6, IL-1, IL-8, and high antibody responses to some antigens
are associated with chlamydial responses in the reproductive
tracts of infertile women and Chlamydia-infected women (a no-
table caveat being that much of the evidence is from uncompli-
cated infections).
Examination of the effects of chlamydial infection in human
tissue ex vivo has provided a controlled insight into the cellular
responses that likely occur in vivo immediately upon primary in-
fection. Through ex vivo fallopian tube studies, Hvid et al. (56)
showed that the addition of IL-1 receptor antagonists blocked the
IL-1 and IL-8 induced in response to Chlamydia and this pre-
vented the pathology from chlamydial infection (56). This con-
firms that IL-1 and IL-8 are likelymajor factors in tubal pathology
(56), supporting the cellular paradigm of pathology development
and not supporting the hypersensitivity model. This study further
implicates the innate immune response as a possible determinant
of infection outcome.
Fallopian tube explants from women with ectopic pregnancy
who were C. trachomatis seropositive were used to demonstrate
that C. trachomatis induced higher expression of a prokineticin
receptor via TLR2 binding (57). The prokineticin pathway im-
pacts smooth muscle contraction and intrauterine implantation,
as well as angiogenesis, which may imply a mechanism for C.
trachomatis damage leading to ectopic pregnancy (57). T lympho-
cytes from endometrial and salpingeal tissues cultured ex vivo in
the presence of Chlamydia or cHSP60 showed induction of lym-
phocyte proliferation and IFN- secretion from PID or ectopic
pregnancy cases compared to cell lines (58). In the same patients,
higher levels of IFN-mRNA expression and lower levels of IL-5
in fallopian tube and peritoneal cavity specimens from PID pa-
tients who had T cells proliferating in response to the organism ex
vivo further implicated Th1 cytokine production in C. trachoma-
tis-related pathology (58). However, it is important to note that
these Th1 responses may be required to resolve the infection, and
the clearance compared to the tissue pathology results from a Th1
profile immune response are not well understood. Primary endo-
cervical cell cultures infected with C. trachomatis also demon-
strated a proinflammatory cytokine response, with abundant pro-
duction of IL-8, IL-1, and TNF-, all of which were maximally
detected during live infection with active bacterial protein synthe-
sis (59). These primary endocervical cultures indicate that the in-
nate immune response to Chlamydia is typically proinflamma-
tory, which is what may be required to successfully resolve the
infection. Combined, these data predominantly support the cel-
lular paradigm and ascending infection models of pathology and
link to a Th1 profile of immunity. However, given that a cytotoxic
response is needed to resolve an infection, differentiation between
a successful Th1 profile or response associated with resolution of
infection and one that results in tissue damage is not possible in
the absence of longitudinal data.
Immune Responses in PBMC in Women
PBMC are often used to provide insight into how immune cell
responses to Chlamydia relate to the patient infection or disease
status. PBMCproliferation induced by purifiedC. trachomatisEBs
showed prominent secretion of IFN- in women with genital in-
fections (60). In a separate study, PBMC from healthy donors
were incubated with C. trachomatis serovar K, leading to the find-
ing that proinflammatory gene expression (measured bymicroar-
ray and validated by quantitative reverse transcription-PCR) was
sustained for up to 7 days, especially for IFN-, and IL-2 receptor
 (61). However, in one report, cHSP60-stimulated PBMC pro-
duction of IFN- was lower in women with PID or repeat infec-
tions than in women with current infections (62, 63). Dendritic
cells prepared from human PBMC were infected with C. tracho-
matis serovar E or L2, which induced the production of IL-1,
IL-6, IL-8, IL-12p70, IL-18, and TNF- (64). Production of IL-12
and TNF- by human PBMC-sourced dendritic cells infected
withC. trachomatis L2 was reported (65). Hook et al. (66) showed
that stimulation of PBMC with chlamydial EBs elicited IFN-
production by natural killer cells. Cohen et al. (67) showed that
IFN- production from PBMC stimulated with cHSP60 corre-
lated with patients who were protected from acquisition of infec-
tion in a longitudinal study of 143 female patients (67). This study
also showed that the PBMC production of IL-13 in response to
chlamydial EBs also correlated with a reduced risk of infection
(67). Our own research has demonstrated IL-6 production from
endometrial and endocervical primary ex vivo cultures from live
infections with C. trachomatis (68).
Immune Pathway Elucidated by In Vitro Culture Models
Epithelial cell cultures are most commonly used for in vitro
growth and characterization of C. trachomatis infection (69). C.
trachomatis infection of HeLa cells, SiHa human cervical carci-
noma epithelial cells, andHEp2 human epithelial cells was used to
demonstrate that IL-1 regulates IL-8 production in these cell
lines during infection (70). Similarly, mRNAmeasurement of cy-
tokine expression afterC. trachomatis infection ofHeLa cells, SiHa
cervix squamous carcinoma cells, and HT-29 colon adenocarci-
noma cells showed increased levels of IL-8, GRO, granulocyte-
macrophage CSF, IL-6, and IL-1 (59). AHeLa–THP-1 coculture
model attempting to recapitulate the in vivo cellular cross talk also
identified IL-6 and IL-8 cytokine secretion that was sustained dur-
ing C. trachomatis infection with IL-1 transiently detected (71).
IL-6 and IL-8 were also detected by using cervical and epithelial
cell infectionmodels (59). AHeLa and THP-1 (mononuclear cell)
coculture model found that there are distinct profiles of innate
immune responses toC. trachomatis serovars E and L2. The results
also showed a difference between the two serovars in the effective-
ness with which monocyte-released innate cytokines (such as
TNF-) controlled the infection in an epithelial cell model (72).
Using a similar coculturemodel, our team also demonstrated sus-
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tained IL-6 production in response to C. trachomatis L2 infection
(59). Examination of host and chlamydial gene expression by a
high-throughput RNA sequencing method enabled the investiga-
tors to identify a fibrotic profile of gene expression being in-
duced in infected HEP-2 cells (73), although it would be inter-
esting to see the outcome of the same experiment with a
reproductive tract cell line or primary ex vivo studies. The role
of TNF- in the inhibition of chlamydial development was
evaluated by the addition of recombinant TNF- to Hep2 cells
prior to infection, which resulted in smaller inclusion bodies
(74). Furthermore, addition of IFN- to the cell line showed
that, in combination with TNF-, chlamydial replication was
inhibited (74). Lu et al. (75) showed that chlamydial infection
of several epithelial cell lines resulted in the secretion of mature
IL-18. IL-18 is known to potentiate the Th1 immune response
and enhance the production of IFN- (75).
Recently, two teams demonstrated important links among
apoptosis, cell survival, and carcinogenesis for Chlamydia (76,
77). They demonstrated that sustained p53 downregulation is the
key event that prevents apoptosis in Chlamydia-infected cells and
that this is actively mediated by Chlamydia via the p53-MDM2
axis and ubiquitination (76, 77). These important in vitro findings
demonstrate that it is not just via innate immune and pathogen
defense pathways that Chlamydia impacts the cell, but other cen-
tral host cell pathways are also fundamentally required for the
pathogen’s survival. These studies support the ideas that IFN-
has a central role in the immune response and quite probably
infection clearance or prevention of infection and that, poten-
tially, the level or combination of the immune responsemaymod-
ulate the resolution or pathological outcome of infection.
Conclusion
Overwhelmingly, the studies of in vivo responses, ex vivo cul-
tures, and laboratory cell culture models all support a higher
level or predominance of a Th1 or cytotoxic profile of immune
response to chlamydial infection, with IFN-, IL-8, IL-1, and
IL-6 findings featuring almost universally in the studies (al-
though IFN- was also associated with protection against a
repeat infection). However, it is not clear if the type or level of
pathological response is moderated or different between women
who develop pathology and those who resolve the infection
without pathology. Longitudinal sampling and analysis of cor-
relates of the local immune response, the PMBC response, and
infection clearance relative to the initial infection burden with
the development of upper reproductive tract pathology is one
possible study design that could help to clarify the contribution
of proinflammatory primary immunity.
HOST/HUMAN FACTORS ASSOCIATED WITH CHLAMYDIAL
INFERTILITY IN WOMEN
Repeat Infection and Infertility
Repeat infection represents a substantial proportion of the
chlamydial infections detected annually (reinfection review in
reference 78). It is likely that these repeat infections are made
up of reinfections, treatment failures, and persistent infections
(79). Batteiger et al. studied a longitudinal cohort of 210 ado-
lescent women (14 to 17 years old) in the United States and
found that 121 experienced repeat infections (79). In a longi-
tudinal cohort in Australia, 1,116 women (16 to 25 year old)
were followed up and 14 reinfections were observed in a total of
81 women who were at risk of repeat infection (3 of these had
two episodes of reinfection) (cumulative risk over 12 months
of 20.3%; 95% confidence interval [CI], 13.2 to 37.6%) (32).
Interestingly, in this study in Australia, the organism load was
lower in reinfections than in prevalent infections detected at
the study baseline (32) but there were no associations between
patient characteristics and reinfection (32) (possibly because
the study was underpowered to detect an effect). However,
careful consideration of the study design is needed when eval-
uating repeat infection; the studies of Batteiger et al. and
Walker et al. tested quarterly for Chlamydia, and PCR may de-
tect residual DNA from dead organisms causing a false positive
(i.e., increased frequency or timing of specimen collection can
overestimate repeat infection). A study conducted in Vancouver,
Canada, showed that repeat infections occurred in 8 of 42 patients
in a longitudinal study (both genders), indicating a cumulative
incidence of 29% (95% CI, 12 to 46%), although the study was
confounded by the immediate retesting of some patients (80). A
study in the United Kingdom showed that the reinfection rate was
29.9 (range, 19.7 to 45.4) per 100 person years in a general practice
clinic setting (81). Interestingly, it appears that women who re-
solve their infections spontaneously between diagnosis and re-
turning for treatment are more protected from a repeat infection
(82). As we would expect, infection and repeat infection are sig-
nificantly associated with sexual behavior risk factors such as new
partners or failure to use condoms (32). These repeat infection
rates appear to be higher than the reported infertility outcome
rates of women who had a positive Chlamydia test in the retro-
spective cohort study of Low et al. (16), suggesting that repeat
infection is not the sole determinant of infertility or pathology.
However, there is evidence that repeat infection increases the risk
of developing infertility. A retrospective cohort study byHillis and
coworkers in Wisconsin examined the risk of hospitalization for
ectopic pregnancy or PID in women who had one or more chla-
mydial infections (n  11,000). They identified higher risks of
ectopic pregnancy in women who had two (odds ratio [OR], 2.1;
95% CI, 1.3 to 3.4) or three or more (OR, 4.5; 95% CI, 1.8 to 5.3)
chlamydial infections (83). The PID risk was also higher for
womenwhohad two (OR, 4.0; 95%CI, 1.6 to 9.9) or three ormore
(OR, 6.4; 95% CI, 2.2 to 18.4) chlamydial infections (83). There-
fore, repeat infection is likely to be a significant contributing factor
in at least some cases of chlamydial infertility.
Treatment failures induced by antibiotics have also been pro-
posed to contribute to repeat infection rates (reviewed in refer-
ence 84). Batteiger et al. (79) showed that repeat infections in
13.7%of their patients were due to possible or probable treatment
failures. Additionally, in vitro studies have shown that azithromy-
cin induces chlamydial persistence or heterotrophic resistance
(84–87). Therefore, treatment failure or perhaps indirect failure
via persistence could be a contributing factor in the development
of infertility in some women via all of the proposed mechanisms.
The rise of repeat infections detected over time has resulted in
the proposal that increased public health investment in chlamyd-
ial screening and treatment is preventing the development of nat-
ural immunity to the infection (arrested-immunity hypothesis)
(88, 89). Furthermore, the authors propose that these repeat in-
fections may be the source of pathological sequelae that may not
occur in women who have protective immunity from a naturally
resolved infection (88, 89).
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Do Coinfections or the Microbiome Play a Role in
Chlamydial Pathology?
Coinfections with other STIs are common; for example, 46% of
female patients positive for Neisseria gonorrhoeae were also posi-
tive for Chlamydia in a family planning clinic in the United States
(90). However, a serology study in Zimbabwe demonstrated that
women with antibodies to either C. trachomatis orN. gonorrhoeae
were significantly more at risk of having PID, ectopic pregnancy,
or abnormal fallopian tubes than were women with antibodies to
both pathogens (91), suggesting that infection with both patho-
gens is not necessary for reproductive pathology. But this study
needs to be interpreted with caution, as the antibody tests for the
gonococcus are not sufficiently sensitive. Numerous studies have
implicated bacterial vaginosis in chlamydial infection (92–96).
Patients with bacterial vaginosis who had recent contact with a
male with chlamydial urethritis had an OR of 3.4 (95% CI, 1.5 to
7.8) to test positive for chlamydial infection. The presence of
H2O2-producing lactobacilli in the vagina were protective against
the acquisition of infection (OR, 0.4; 95% CI, 0.2 to 0.8) (93).
Recently an in vitro model was used to demonstrate that it is ac-
tually the acid or pH-lowering impact of lactobacilli that confers
antichlamydial activity (97). It has been hypothesized that indole-
producing organisms that increase in the microbiome during or
subsequent to bacterial vaginosis enable C. trachomatis to synthe-
size tryptophan from indole (98), consequently evading the activ-
ity of IFN- at the infected site, and thus may facilitate infection
(40, 98). Bacterial vaginosis during C. trachomatis or N. gonor-
rhoeae infection was recently found to be associated with a risk of
PID, although the authors conclude that it is difficult to determine
if the bacteria underlying the vaginosis facilitated ascension and
PID caused by the STIs or, alternatively, if the bacteria responsible
for vaginosis cause the PID (99). Clearly, there is an increased
chlamydial infection risk associated with coinfection or bacterial
vaginosis and also evidence of an associationwith PID, supporting
the idea that coinfections could therefore result in an increased
likelihood of development of infertility.
Sexual Behavior and Age of Sexual Contact
Age is a risk factor in the likelihood of contracting a chlamydial
infection, with younger people at higher risk (10, 100). Cross-
national studies from 1999 to 2008 in Denmark, Australia, and
Sweden showed that increasing PID rates were associated with
increasing age (15 to 19 year olds generally had the lowest number
of cases per 100,000 women, while 30 to 34 or 35 to 39 year olds
had the highest number of cases per 100,000 women), with the
exception of New Zealand, where the rates were higher in women
15 to 19 years old (101). The highest incidence of C. trachomatis
infection is in women 16 to 24 years old (32). Consistent with
these studies, being under 20 years old and presenting with cervi-
cal symptoms were risk factors for endocervical chlamydial infec-
tion in women, and the organism burden was also higher in
younger women when measured by viable culture counts (102).
Sexual behavior (new partners or a higher number of partners)
is often significantly associated with an increased risk ofC. tracho-
matis infection (7, 103). As shown in the study by Skjeldestad et al.
(104), where there was a 37%probability of a woman acquiringC.
trachomatis infection if she has had three or more partners within
42months. A younger age at first coitus, a higher number of sexual
partners, and a self-reported history of medically diagnosed STI
were all significantly associatedwith tubal infertility, in contrast to
fertile controls (P 0.01) (105). However, as these are also known
to be significant factors in the increased likelihood of acquisition
of chlamydial infection, it is not certain if they directly influence
the likelihood of pathology outcomes from the infection.
Hormonal Status at Time of Infection
Oral contraceptive use was found to be a risk factor for C. tracho-
matis infection (P 0.006), and the organism burden was found
to be higher in oral contraceptive users (P  0.001) (102). Pro-
spective recruitment of young female patients (17 years of age)
attending genitourinary medicine clinics in the United Kingdom
found that those who had a Chlamydia infection were also more
likely to have elevated progesterone concentrations (P  0.05)
(106). In contrast, oral contraceptive use has been linked to pro-
tection from subsequent infertility or conception problems by two
different studies (12, 107). However, it would be extremely diffi-
cult to link hormone status at time of infection with subsequent
pathological outcomes such as infertility, even in a longitudinal
study, given the high numbers of oral contraceptive users and the
independent importance of these factors in the risk of acquiring an
infection.
Human Genotypic Factors Associated with C. trachomatis
Infertility in Women
The development ofC. trachomatis-related infertility in only some
women may be a consequence of a genotypic predisposition (re-
viewed comprehensively in reference 108). These studies are de-
scribed below; however, for the sake of brevity, we have docu-
mented the sample sizes, statistics, and details of the alleles in
Table 1. Note that since a comprehensive review of this topic
(mentioned above) has recently been published, this section is
brief (108).
TLRs recognize and bind to antigens of a pathogen and signal to
upregulate an immune response. TenTLRs have been identified in
the human body, and TLR1 to TLR4 are expressed in the female
genital tract (109). TLR2 and TLR4 are also expressed on various
cells (110). In a prospective genotypic study with female patients
attending a sexual health clinic and a fertility clinic in Amsterdam,
Netherlands, Karimi et al. (111) demonstrated a possible protec-
tive role for a TLR2 haplotype. The haplotype, consisting of two
distinct single nucleotide polymorphisms (SNPs), was found to be
present in a significantly higher proportion of women with a his-
tory ofChlamydia infectionwho did not have tubal pathology and
in sexual health clinic attendees and was present in a higher pro-
portion of women who were asymptomatic (111). In the PEACH
PID study TLR1 and TLR4 polymorphisms were found to be sig-
nificantly associated with chlamydial PID (112), while SNPs from
TLR2 (SNPs different from those included in the study of Karimi
et al.), TLR6,Myd88, and TIRAPwere not significantly associated
with chlamydial PID (112).
den Hartog et al. (113) found that the risk of tubal pathology
was higher in C. trachomatis IgG-positive women with multiple
TLR polymorphisms. That study also showed a trend toward the
association of various individual polymorphisms in TLR9 and
TLR4 with an increased risk of tubal pathology in C. trachomatis
IgG-positive women (113). However, the small sample size in that
study makes it difficult to draw a correlation between the poly-
morphisms and the level of risk of female infertility.
NLRP3, a component of the inflammasome that activates a pro-
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inflammatory response, has been found to have polymorphisms
reported to result in altered secretion of IL-1 (a proinflamma-
tory cytokine) (114). Several NLRP3 polymorphisms were tested
in women prospectively recruited at a sexual health clinic and
fertility clinics in Amsterdam; women heterozygous or homozy-
gous with the one of the NLRP3 polymorphisms were at signifi-
cant risk of developing abdominal pain during C. trachomatis in-
fection (114).
Mannose-binding lectin (MBL) is a proinflammatory protein
that activates complement and is locally synthesized in the vagina
(115). MBL andMBL promoter polymorphisms have been previ-
ously demonstrated to alter the levels of MBL produced (115). It
was found that womenwith TFIwhowereChlamydia seropositive
more frequently had the low-MBL-producing genotypes than did
healthy controls (115). However, this was not the case in an ecto-
pic pregnancy group, who were less likely to have the MBL-defi-
cient genotypes (115). The latter finding sheds some doubt on the
role of MBL genotypes, given that it seems likely that the pathol-
ogy associatedwith chlamydial ectopic pregnancy is similar to that
resulting in chlamydial tubal infertility.
Human leukocyte antigen (HLA) class II molecules (DR, DQ,
and DP) present peptides to CD4 T cells and induce adaptive
immunity. DQ polymorphisms were more frequent in women
with tubal infertility who were also C. trachomatis seropositive
(116), while another polymorphism was negatively associated
with C. trachomatis tubal infertility (116). Wang et al. (117)
showed that in adolescent females with recurrent chlamydial in-
fections, certain HLA polymorphisms were significantly associ-
ated with recurrent infections. A recent study attempted to link
different immune genotypes to immunological outcomes by test-
ing a functional role for HLA DQ alleles combined with an IL-10
allele both for frequency in a TFI (Chlamydia-positive) cohort
compared to controls and for a lymphocyte proliferative response
to cHSP60 (118). The HLA alleles and IL-10 allele were more
frequently identified in the chlamydial tubal factor cohort than in
the controls; however, the lymphocyte proliferation in response to
cHSP60 was not significantly different in relation to the alleles
(118). However, in a different study, distinct IL-10 and IFN-
polymorphisms were found to have a significant impact on lym-
phocyte proliferation in response to chlamydial antigens (119).
A range of cytokine polymorphisms have been shown to signif-
icantly associate with women with C. trachomatis tubal infertility,
including IL-10 (120), TNF- (120), and IL-12 (121). Polymor-
phisms in IL-1 and receptor genes were not associated with C.
trachomatis-related tubal pathology (122). Adolescent females
with recurrent chlamydial infections had a lower frequency of
three IL-10 promoter polymorphisms (117). Eng et al. (123) dem-
onstrated that a CD14 allele (TLR-4 coreceptor) was associated
with increased TNF- production when whole blood was stimu-
lated with C. trachomatis and C. pneumoniae (124).
While none of these studies were able to account for all chla-
mydial tubal infertility cases, they are a convincing body of evi-
dence that the human genotype may be a factor in pathology de-
velopment. It is interesting that most of the studies done to date
have focused on immune factors, yet as an obligate intracellular
pathogen, Chlamydia has key nutritional, inclusion vacuole, and
structural requirements, and therefore, the ability to ascend and
cause pathology may, in fact, be independently determined by an
as-yet-unknown host genotype that could relate to these nutri-
tional and structural requirements.T
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PROPOSED MECHANISMS OF THE DEVELOPMENT OF
INFERTILITY FOLLOWING C. TRACHOMATIS INFECTION IN
WOMEN
Wedescribe what we consider to be fourmechanisms or processes
of host-pathogen interaction that are commonly referred to in the
field to explain the process that underlies the development of in-
fertility following Chlamydia infection. The processes are not ex-
clusive of each other, and there is evidence for and against a role
for each process.Wewill briefly summarize these processes so that
the host and pathogen data we have reviewed can be considered in
the context of each process or mechanism (Fig. 1).
Ascension
It is often suggested or assumed that infection ascends to the upper
reproductive tract in only some women, and if it is unchecked,
once it is in the upper reproductive tract, it results in the develop-
ment of tubal pathology. There is considerable direct evidence
that a chlamydial infection can ascend beyond the cervix; how-
ever, it is not known if ascension occurs without development of
tubal pathology. Evidence of ascension includes the detection of
Chlamydia DNA in salpingectomy specimens from one woman
with ectopic pregnancy and in several endometrial and cervix
specimens from women with subsequent ectopic pregnancy al-
though not in their ectopic salpingectomy specimens (125). C.
trachomatis DNA was detected in tubal specimens from women
with ectopic pregnancy in Myanmar (126). C. trachomatis DNA
was detected in the endometrium, fallopian tubes, and ovaries of
as many as 56% of women with ectopic pregnancy or TFI (127).
The presence of C. trachomatis organisms was associated with en-
dometritis (plasma cell influx in the endometrium) (128, 129). A
small study in the United Kingdom identified the presence of C.
trachomatis in the upper genital tracts of 4 of 10 women, all of
whom had no symptoms (130).
It seems possible or even likely that ascension is independently
moderated by numerous other factors that could explain the low
frequency of pathology development, supporting the idea that it
occurs only in some women. These moderating factors could in-
clude host factors such as cycle stage or hormone status at the time
of infection, as chlamydial or gonococcal endometritis was found
to be more likely to be detected in women in the proliferative
phase (94). Equally important moderating factors could include
immune status, genotypic factors, other coinfections, or repro-
ductive tractmicrobiome composition. Unfortunately, there is no
published evidence on these factors or direct evidence that ascen-
sion does or does not occur. Furthermore, pathogen factors could
also moderate the likelihood of ascension, such as the infectious
burden (although it has not been possible to significantly associate
the chlamydial serovar alone with pathogenic potential or clinical
manifestations [131]). Certainly, it seems widely agreed upon that
ascension and presence of the pathogen, rather than an indirect
process such as molecular mimicry, are involved in pathology de-
velopment. Yet it seems that ascension of the infection may also
occur without pathology, so ascension may not be the primary
determinant of pathology.
Persistence
Chlamydia persistence, or the presence of viable but noncultur-
able chlamydial organisms (visualized as aberrant forms), de-
FIG 1 The four major models of development of pathology associated with chlamydial infertility in women. Shown are the four models summarized here that
are supported within the field by evidence from human studies.
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velops in response to various conditions and can remain dor-
mant for considerable lengths of time (reviewed in reference
132). In this review, we refer to in vivo correlates of the in vitro
chlamydial persistent forms that remain indefinitely associated
with cells and dormant and able to be reactivated. This is not
the same as infections with other microbes that are referred to
as “persistent” because the infection failed to respond to anti-
microbial treatment. Persistence in vivo has been proposed as a
model where this continued presence of the organism in aber-
rant body forms may drive a long-term pathological immune
response resulting in tissue damage to the fallopian tube (cer-
tainly, the high expression of the dominant antigen cHSP60 has
been detected in laboratory persistence models) (reviewed in
reference 133). There are studies that have presented evidence
of C. trachomatisDNA or antigens being present in the tubal ma-
terial of women with tubal infertility or ectopic pregnancy or sal-
pingitis, supporting the idea that organism persistence in some
form occurs in vivo (127, 134–136). Recently, morphologies con-
sistent with laboratory models of persistence were observed in
endocervix samples associated with IFN-, further supporting the
likely in vivo relevance of laboratory models of persistence (55). It
is difficult to determine if chlamydial persistence leading to pa-
thology has always occurred. Persistent infection may resolve at
any time after pathology develops and prior to detection, and
given the difficulties of specimen collection from the upper genital
tract, the evidence is reasonably compelling that chlamydial per-
sistence (consistent with either the lab models or a distinct in vivo
form) is a relevant factor in pathology.
It is important to note a recent review that suggested that some
forms of persistence may be “colonization” and in fact not asso-
ciated with “pathogenesis” and disease (137). Our suggestion is
that perhaps the two are distinct and that pathology-associated
persistence (given the evidence reviewed here) and separate cases
of nondamaging colonization occur. Specifically, the evidence
that (i) chlamydial persistence is induced by a range of relevant
conditions in vitro (reviewed in references 132 and 133) and (ii)
persistence-likemorphology and/or chlamydial antigen/DNA de-
tection in the absence of active infection has been observed in
clinical samples leads us to feel confident enough to suggest that
persistence may be a relevant physiological status in vivo, particu-
larly in the case of ascension to the upper reproductive tract tis-
sues, and therefore likely a factor in a pathological outcome of
infection.
Cellular Paradigm
The cellular paradigm mechanism proposes that the Chlamydia-
infected epithelium immediately responds to the presence of the
Chlamydia or specific antigens from Chlamydia in a proinflam-
matory manner, typified by proinflammatory cytokines and
growth factors, which in turn induces a proinflammatory second-
ary immune cell activation and migration to form a local lym-
phoid follicle, resulting in cell damage and fibrosis or scarring
(comprehensively presented and reviewed in reference 138). It is
important to note that a proinflammatory response is also needed
for clearance of the infection, given that the organisms is an intra-
cellular pathogen (139). This mechanism is widely supported by
the published evidence of human epithelial and immune cell re-
sponses to Chlamydia and a primary tissue ex vivo model that is
discussed in more detail below. This mechanism also presumes
that chlamydial ascension is associated with pathology and also
mutually allows the persistence of Chlamydia in the upper repro-
ductive tract (138). A pathological adaptive memory response
proposed as the secondary component of this mechanism is also
supported by the existing data that repeat infections increase the
likelihood of pathological outcomes in women (83) and by nu-
merous immunological results (as discussed here). However, it is
also important to note that repeat infections would induce new
acute or innate inflammatory responses that could drive the pa-
thology independent of the secondary phase of the cellular para-
digm mechanism.
cHSP60-Induced Delayed Hypersensitivity
There has been considerable focus on a mechanism that involves
delayed hypersensitivity and/ormolecular mimicry in response to
specific chlamydial antigens (reviewed in reference 140). This has
largely resulted from a body of literature demonstrating high-titer
human antibody responses to cHSP60 in patients with tubal pa-
thology and additionally that, in several animal models, tissue
pathology developed after repeated inoculations with cHSP60
protein (reviewed in reference 138).However, thismechanism is a
subject of considerable controversy because of inconsistencies be-
tween the different published findings, i.e., problems with protein
preparations that involved a hypersensitive detergent being used
in some animal models and cross-reactivity or poor specificity of
some of the antibody tests (141–147). On the other hand, there is
no doubt that cHSP60 is a predominant chlamydial antigen that
does frequently elicit an immune response. Furthermore, in hu-
man trachoma cases, it is frequently possible to observe ongoing
follicles present and disease pathology in the absence of PCR-
detectableChlamydia, suggesting that there is continuing immune
activity in the absence of the organism during pathology develop-
ment (148).
Interestingly, one group has proposed that cHSP60 antibod-
ies detected in the follicular fluid of female in vitro fertilization
(IVF) patients may induce early destruction of the embryo by
cross-reacting to embryo human HSP60 and result in lower
transfer success (149). They observed 74.1% cHSP60 seropos-
itivity in women without embryo implantation (n  47) and
47.9% seropositivity in women with successful embryo im-
plantation (n  91) (P  0.0004). However, this observation
directly contradicts a finding of a separate and much larger
study (n  1,279) that cumulative IVF cycle pregnancy rates
are the same for women who are Chlamydia seropositive and
those who are seronegative (150). A study in France also contra-
dicted a possible role for antichlamydial immunity in embryo im-
plantation failure, as it was found that the semen characteristics
and IVF pregnancy rate of men and women with either PCR or
serological evidence of Chlamydia (n  52) were not different
from those of controls who were negative by chlamydial testing
(n 119) (151).
CONCLUSIONS
A better understanding of the pathogenesis of Chlamydia-asso-
ciated infertility and the risk factors associated withC. trachomatis
infertility would enable specific screening for at-risk women and
inform the development of a vaccine designed to prevent the
progress of infection to infertility or pathology. While there are
several convincing mechanisms that have been presented to ex-
plain how the disease pathology occurs, each with some support-
ing evidence from the human data reviewed here, the actual pro-
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cess or host and pathogen factors that result in infertility remain
uncertain and require further investigation. It is clear that a pro-
inflammatory response is largely elicited in response to chlamyd-
ial infection. Whether this response or the extent of this response
is the primary determinant of pathology remains unclear. Cer-
tainly, it is essential to have at least IFN- (considered a proin-
flammatory cytokine) andother proinflammatory activity for suc-
cessful resolution of the infection. Furthermore, while there are
tantalizing associations, there are not yet definitive correlates of
the contributions ofmany host and pathogen factors to pathology
risk, including human genetic polymorphisms, C. trachomatis se-
rovar- and genotype-specific distinctions, coinfection or micro-
biome parameters, and risk behaviors like repeat infections or age
at sexual debut (summarized in Fig. 2). A comprehensive and
extended longitudinal analysis of each of these factors in a study of
a very large cohort of women prior to any infection from the early
teen years until postpregnancy age (with adequate statistical
power) would be the most robust way to monitor disease factors
and pathology outcomes for women (although such a studymany
not be feasible). Certainly, there is sufficient evidence that primary
chlamydial screening is important to prevent PID and TFI. Iden-
tification of the major contributing factors to disease pathology
would better inform the design of future vaccines and would also
enable the design of molecular diagnostics for early detection of
women at risk of pathology development.
In the absence of such comprehensive knowledge and subse-
quent preventive interventions (enhanced diagnosis or vaccine),
there is a real opportunity to alleviate some of the risks and costs
associated with the pathological outcome of infection by improv-
ing guidelines for screening, as recently proposed in the United
Kingdom (152). In addition to this, we propose that the improved
use of a serological diagnosis of pathology risk, expediting infer-
tility diagnosis for women and also as a tool to predict the risk of
ectopic pregnancy or PID in women (20, 150) who have had chla-
mydial infections, should also be rigorously evaluated and consid-
ered for routine implementation in both fertility and general prac-
tice clinic settings.
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